Indeed, a report showed that melanoma with positive NY-ESO-1 immune response responded to anti–CTLA-4 therapy [46], and other reports showed that lung adenocarcinoma with serum NY-ESO-1 antibody responses had a better clinical efficacy to anti-PD-1 therapy than those without antibody responses [47, 48]. This evidence concerns the gene CTLA4 and melanoma.